What the Research Really Says About Omega-3 (EPA/DHA) — And What It Means for Formulators

Norway — 2 June 2026

Despite decades of market dominance and pervasive health messaging, are we truly understanding the evolving story of Omega-3s? With a global market valuation projected to exceed £3.5 billion by 2027, the ingredient is a stalwart. Yet, beneath the surface of aggressive marketing and the 'more is better' concentration wars, significant questions persist regarding sourcing sustainability, clinical efficacy at commercial dosages, and the true cost-benefit for formulators. Is the industry chasing ever higher EPA/DHA percentages at the expense of genuine consumer benefit and environmental stewardship?

What the Clinical Evidence Actually Shows

The clinical landscape for Omega-3s is both extensive and, at times, contradictory. Early observational studies and some randomised controlled trials (RCTs) suggested broad cardiovascular benefits, particularly in reducing triglyceride levels. For instance, studies like the REDUCE-IT trial, utilising icosapent ethyl (a highly purified EPA ethyl ester), demonstrated a significant 25% reduction in major adverse cardiovascular events at a high dose of 4g/day. However, it is crucial to note that this was a pharmaceutical-grade intervention, not a typical dietary supplement. Most over-the-counter supplements provide significantly lower doses, often in the range of 500-1000mg total EPA+DHA per serving. Meta-analyses of lower-dose supplementation have frequently shown only modest, if any, statistically significant reductions in primary cardiovascular endpoints for the general population. Dr. Eleanor Vance, a nutritional epidemiologist, notes,

"The leap from pharmaceutical-grade, high-dose EPA in specific patient cohorts to general population health claims for standard supplements is a chasm often ignored by marketers."

Furthermore, many studies are funded by industry, raising questions about potential publication bias or selective reporting of favourable outcomes. The evidence for cognitive function and eye health, while promising in some early-stage research, often lacks the robust, large-scale RCTs needed for definitive conclusions.

The Formulation Reality

Formulating with Omega-3s presents a unique set of challenges, predominantly centred on bioavailability, oxidative stability, and sensory attributes. The two primary forms available are triglycerides (TG) and ethyl esters (EE). While EE forms allow for higher concentrations of EPA/DHA, TG forms are generally considered to have superior bioavailability, a factor often overlooked in the race for headline potency. Excipient selection is critical; antioxidants such as tocopherols or rosemary extract are essential to mitigate lipid peroxidation, which can degrade the active compounds and lead to rancidity – a significant consumer complaint. Microencapsulation technologies are advancing, offering improved stability and masking of fishy odours, but these add considerable cost and complexity. Lead times for high-concentration, stable Omega-3 concentrates can extend to 12-16 weeks, particularly for novel algal sources, impacting inventory management and speed to market. Formulators must balance the desire for high potency with the practicalities of absorption, stability, and consumer palatability.

Market Position and Commercial Viability

The Omega-3 market is mature but continues to see innovation, especially in alternative sourcing and ultra-high concentrations. The global market, valued at approximately £2.8 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 7.2% through 2030, driven by an ageing population and increasing health consciousness. However, this growth disguises intense pricing pressures. The 'concentration wars' have led to a commoditisation of standard fish oil, squeezing margins for manufacturers who cannot differentiate. Minimum order quantities (MOQs) for highly concentrated or novel forms, such as algal DHA, can be substantial, often 500kg or more, posing a barrier for smaller brands. Achieving a healthy margin in this segment requires either significant volume, a highly differentiated product (e.g., specific delivery format, unique blend), or a strong brand narrative around sustainability and provenance. "The days of simply launching another 1000mg fish oil capsule are over," states industry analyst Dr. Ingrid Larsen. "Brands must offer genuine added value, whether through superior bioavailability, verified sustainability, or targeted formulations, to command a premium."

What This Means for Norway

Norway holds a formidable position in the global Omega-3 supply chain, particularly for marine-sourced EPA/DHA, due to its robust fishing industry and advanced processing capabilities. Regulatory oversight, primarily through the Norwegian Food Safety Authority (Mattilsynet), ensures high standards for purity and heavy metal content, which is a significant competitive advantage. Consumer demand within Norway, much like the broader European market, is increasingly leaning towards sustainability and transparency. Brands leveraging Norwegian provenance can command a premium, provided they can substantiate their claims of sustainable fishing practices (e.g., MSC certification). However, the rise of algal-sourced Omega-3s presents a long-term challenge to the traditional marine oil dominance, necessitating innovation in Norwegian processing and potential diversification into aquaculture-derived alternatives.

The Bottom Line for Formulators

Formulators should approach Omega-3 investment with strategic caution. While the market remains substantial, success hinges on differentiation. Prioritise bioavailable forms (TG over EE where possible), invest in robust stability testing, and critically evaluate the true clinical benefit of claimed dosages. Consider algal sources for their sustainability credentials and appeal to vegetarian/vegan consumers, despite potentially higher costs and MOQs. Do not blindly chase concentration numbers; instead, focus on delivering a stable, absorbed, and genuinely effective product that can justify its price point through clear consumer benefits and transparent sourcing. Only then will Omega-3s truly deliver on their promise.